Relmada Therapeutics, Inc.
RLMDHealthcare|Biotechnology|US
$3.90
+0.13 (+3.45%)
DCF Value
$0.05
Tangible Book / Share
$1.84
Cash / Share
$1.94
Clinical Trials (11)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06663137 A Study to Evaluate the Safety and Efficacy of NDV-01 in Participants With NMIBC | Non Muscle Invasive Bladder Cancer | P2 | Recruiting | 70 | Open-label | NDV01 intravesical controlled release formulation of gemcitabine and docetaxel |
| NCT07342517 A Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line Therapy | Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive) | P3 | Withdrawn | — | Open-label | NDV-01 (sustained-release gemcitabine-docetaxel) |
| NCT04855760 Safety of REL-1017 for Major Depressive Disorder | Major Depressive Disorder | P3 | Completed | 627 | Open-label | REL-1017 |
| NCT07464145 A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder Cancer | Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive) | P3 | Not Yet Recruiting | 393 | RCT, Open-label | NDV-01 (sustained-release gemcitabine-docetaxel) |
| NCT07313891 A Study of Adjuvant NDV-01 (Sustained-release Gemcitabine-docetaxel) for the Treatment of Intermediate Risk NMIBC Following TURBT | Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Bladder (Urothelial, Transitional Cell) Cancer | P3 | Withdrawn | — | RCT, Open-label | NDV-01 (sustained-release gemcitabine-docetaxel) |
| NCT05081167 A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD) | Major Depressive Disorder | P3 | Completed | 232 | RCT, Double-blind | REL-1017, Placebo |
| NCT04688164 A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD) | Major Depressive Disorder | P3 | Completed | 227 | RCT, Double-blind | REL-1017, Placebo |
| NCT03051256 Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD | Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant | P2 | Completed | 62 | RCT, Double-blind | REL-1017, Placebo |
| NCT03638869 Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of REL-1017 (d-Methadone) | Neuropathic Pain | P1 | Completed | 24 | RCT, Double-blind | REL-1017, Placebo |
| NCT03637361 Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of REL-1017 (d-Methadone) | Neuropathic Pain | P1 | Completed | 42 | RCT, Double-blind | REL-1017, Placebo |
| NCT06009003 Individual Patient Esmethadone (REL-1017) Expanded Access Program | Major Depressive Disorder, Depression | NO_LONGER_AVAILABLE | — | — | REL-1017 |